Active, not recruitingPhase 3NCT07082816
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
Studying NON RARE IN EUROPE: Primary adult open-angle glaucoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alcon Research
- Principal Investigator
- Clinical Trial Lead, PharmaAlcon Research, LLC
- Intervention
- Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution(drug)
- Enrollment
- 489 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2026
Study locations (30)
- Trinity Research Group, Dothan, Alabama, United States
- Eye Doctors of Arizona, Phoenix, Arizona, United States
- Orange County Ophthalmology Medical Group, Garden Grove, California, United States
- United Medical Research Institute, Inglewood, California, United States
- Eye Research Foundation, Newport Beach, California, United States
- North Bay Eye Associates, Petaluma, California, United States
- Sacramento Eye Consultants, Sacramento, California, United States
- Central Florida Eye Specialists, DeLand, Florida, United States
- Glaucoma Specialists of South Florida, Delray Beach, Florida, United States
- East Coast Institute for Research, LLC, Jacksonville, Florida, United States
- Central Florida Eye Associates, Lakeland, Florida, United States
- The Eye Institute of West Florida, Largo, Florida, United States
- Lee Shettle Eye, Largo, Florida, United States
- North Georgia Eye Associates, Gainesville, Georgia, United States
- Coastal Research Associates, Roswell, Georgia, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07082816 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Primary adult open-angle glaucoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07354516Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular HypertensionQlaris Bio, Inc.
- RECRUITINGNCT07303257Quality of Life After Glaucoma Surgery: Evaluating the Patient Perspective Across Surgical OptionsHospices Civils de Lyon
- RECRUITINGPHASE1, PHASE2NCT06921317GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle GlaucomaIVIEW Therapeutics Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT06030193Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)Qlaris Bio, Inc.
- RECRUITINGNANCT06682962Transcorneal Electrical Stimulation for the Treatment of Visual Field Defects in Patients With Open-Angle GlaucomaOkuvision GmbH
- RECRUITINGPHASE4NCT06848946Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery AloneGlaukos Corporation
- RECRUITINGNCT06691555Long-term Safety and Efficacy of a Modified Suprachoroidal Silicone Tube (SST) ShuntDavinci LTD
- RECRUITINGNANCT06607705Changes in Eye Pressure in Glaucoma Patients Treated with Istent Inject W, Monitored by a Contact Lens SensorFundacio Privada Mon Clinic Barcelona
See all trials for NON RARE IN EUROPE: Primary adult open-angle glaucoma →